XenoPort, Inc. announced today top-line results from its pivotal Phase 3 clinical trial of arbaclofen placarbil for the treatment of patients with spasticity due to multiple sclerosis.
[More]
Galapagos NV and AbbVie announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3.
[More]
Men often suffer from more severe cases of psoriasis than women, which may explain why the cost of care for men is higher. This is the conclusion of researchers at Umeå University in a new study.
[More]
Cytokines are molecules produced by immune cells that induce the migration of other cells to sites of infection or injury, promote the production of anti-microbial agents, and signal the production of inflammatory mediators.
[More]
Biogen Idec announced today that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for the marketing approval of ELOCTATE (recombinant factor VIII Fc fusion protein) for the treatment of hemophilia A.
[More]
Prednisone and non-steroidal anti-inflammatory drugs (NSAIDs) can be used for symptom control, but to prevent joint damage, we use disease-modifying anti-rheumatic drugs (DMARDs) including the cornerstone, methotrexate.
[More]
Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces headline results of its Phase 2b trial with its lead product, CT327, in psoriasis patients.
[More]
Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.
[More]
Kinase inhibitors are molecules that block the activity of kinases. Kinases are a specific class of enzymes. They are extremely important in signal transduction processes in the human body meaning that they actually regulate most of the physiological processes that take place in the body.
[More]
US clinicians have demonstrated the benefits of multidisciplinary evidence-based guidelines for the treatment of children with osteomyelitis.
[More]
Biologists at UC San Diego have identified eight genes never before suspected to play a role in wound healing that are called into action near the areas where wounds occur.
[More]
Skin cancer is the most common form of cancer in the United States, with one in five Americans developing it over the course of their lives. It's also one of the most preventable types of cancers.
[More]
Liver fibrosis results from an excessive accumulation of tough, fibrous scar tissue and occurs in most types of chronic liver diseases. In industrialized countries, the main causes of liver injury leading to fibrosis include chronic hepatitis virus infection, excess alcohol consumption and, increasingly, nonalcoholic steatohepatitis (NASH).
[More]
XBiotech announced today enrollment of the first patient into its Phase III trial of Xilonix. The Pivotal study is designed to improve health and survival of late stage colorectal cancer patients with associated cachexia.
[More]
Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A., today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%.
[More]
Researchers have newly associated nine genetic regions with a rare autoimmune disease of the liver known as primary sclerosing cholangitis (PSC). This brings the total number of genetic regions associated with the disease to 16.
[More]
Patients with rheumatoid arthritis (RA) who initiated use of anti-tumor necrosis factor therapies were not at a higher risk of developing herpes zoster (shingles), compared with patients who initiated nonbiologic treatment regimens, according to research from the University of Alabama at Birmingham (UAB) and the Oregon Health and Science University. The findings appeared in the March 6, 2013, issue of the Journal of the American Medical Association (JAMA).
[More]
In response to a recent study that found roughly one-third of prescriptions for autoimmune disease patients go unfilled and a high level of physician mistrust exists among AD patients, the American Autoimmune Related Diseases Association, Inc. has created a new multi-media public service campaign with tools designed to help patients make informed decisions about newly-prescribed therapies and treatments.
[More]
Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its New Drug Application Topicort (desoximetasone) Topical Spray, 0.25%.
[More]
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented data on PV-10 combination therapy today at the American Association for Cancer Research Annual Meeting in Washington, DC.
[More]